As far as we are aware, our report is the first to show that the L1196M mutation in ALK-rearranged NSCLC is related to disease progression during alectinib treatment and that ceritinib can overcome this resistance in the clinical setting. This evidence concerns the gene ALK and non-small cell lung carcinoma.